Shares of Orexigen Therapeutics (NASDAQ:OREX) fell more than 15% this morning on heavy volume after the company announced that the Food and Drug Administration had pushed back its review of the company's resubmitted new drug application for Contrave. As a refresher, Contrave is the company's flagship chronic obesity treatment that will be marketed by Takeda Pharmaceuticals, assuming the drug gets past the FDA. The Prescription Drug User Fee Act action date was set for yesterday, but will now be extended by three months to Sept. 11.
Over the past month, Orexigen shares have risen close to 30% in anticipation of Contrave's approval, so it's not entirely surprising that shares are giving back some of that gain after today's regulatory delay. With that said, let's take a closer look at Orexigen's fall and see if today's dramatic pullback represents a possible buying opportunity.
The obesity market is a tough nut to crack
Even with one in three U.S. adults reportedly being classified as obese, and the numbers only growing worse by the year, Arena Pharmaceuticals (NASDAQ:ARNA) and VIVUS (NASDAQ:VVUS) haven't been able to capitalize on this massive market. The two companies' combined sales for their obesity medications are on track to fall short of $100 million this year, although they were both heavily touted as blockbusters in the making prior to their approvals.
Per comments from the management teams for both companies at various times, the obesity market is in dire need of development from educational and insurance coverage standpoints. Even though Arena's marketing partner Eisai has made significant progress on these fronts in recent months, the obesity space is haunted by the ghosts of drugs past that were plagued by serious adverse events and even deaths.
Orexigen hopes to help usher in a new age for obesity drugs with the approval of Contrave. Keeping with this idea, Takeda is set to roll out a nearly unprecedented marketing effort for the drug following FDA approval.
Perhaps more marketing will do the trick, but it remains to be seen if any drug can generate sizable sales in this market now. I have a hard time believing Orexigen's nearly $800 million market cap heading into this regulatory review properly reflected the present state of the obesity market.
Is the market overreacting to today's news?
Here's the odd part about today's pullback: Contrave's regulatory review is being delayed because the FDA wants more time to put the final touches on post-marketing requirements, as well as the package insert, according to Orexigen's press release. In other words, Contrave looks well on the way to being approved later this year, yet shares are still falling hard.
I suspect today's pullback has more to do with day traders exiting the stock following Orexigen's recent run-up. The stock was set up for a "sell the news"-type event, and this regulatory delay was good enough.
Like its obesity brethren before it, Orexigen shares have now seen their price spike leading into the pivotal regulatory review and subsequently fall for reasons wholly unrelated to the company's underlying fundamentals. While it looks like this pattern could repeat itself heading into September, you should consider Contrave's long-term commercial prospects before investing. After all, trying to time a so-called biocatalyst can backfire in a hurry, evinced by today's action. With that in mind, I think long-term investors might want to take a flier on this obesity drugmaker, at least until the space finally shows some signs of opening up to pharmaceutical therapies.
Leaked: A huge small-cap opportunity
This smart device –kept secret until now – could mark a new revolution in smart tech (with big implications for health care). It’s a gigantic market opportunity -- ABI Research predicts 485 million of its type will be sold per year. To learn about the small-cap stock making this device possible – the stock that could mint millionaires left and right when its full market potential is realized – click here.
George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.